Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Related posts:

1. SDSU researchers awarded NIH grant to understand how autism plays out across the lifespan In the public consciousness, autism spectrum disorder only affects children. In truth, ASD is a lifelong condition. But how it affects older adults is a gaping unknown in autism research. Now, a new and significant grant from the National Institutes of Health will help researchers at San Diego State University understand how the disorder plays out across the lifespan. ...
2. Governments take decisive step towards more affordable vaccines Governments meeting in Geneva for the annual World Health Assembly raised the alarm on Monday over the exorbitant rise in the price to vaccinate a child, passing a resolution urging more affordable... ...
3. Impulsivity linked to binge eating Do you get impulsive when you're upset? If so, this could be putting you at risk for binge eating. The more impulsive you are, the more likely it is you'll binge eat when experiencing negative feelings. ...
4. Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. ...
5. American College Health Association Annual Meeting Join us in Orlando, Florida Tuesday, May 26 through Saturday, May 30, for five days of networking, collaboration, and continuing education at the beautiful Orlando World Center Marriott!Visit Men's Health Network at booth #313!More information here. Dates: Tuesday, May 26, 2015 (All day) to Saturday, May 30, 2015 (All day)Type: Conference ...